PT2519266T - Vacinas de dna infeccioso contra o vírus chikungunya - Google Patents
Vacinas de dna infeccioso contra o vírus chikungunyaInfo
- Publication number
- PT2519266T PT2519266T PT117285403T PT11728540T PT2519266T PT 2519266 T PT2519266 T PT 2519266T PT 117285403 T PT117285403 T PT 117285403T PT 11728540 T PT11728540 T PT 11728540T PT 2519266 T PT2519266 T PT 2519266T
- Authority
- PT
- Portugal
- Prior art keywords
- dna vaccines
- vaccines against
- chikungunya virus
- infectious dna
- against chikungunya
- Prior art date
Links
- 241001502567 Chikungunya virus Species 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 title 1
- 230000002458 infectious effect Effects 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36151—Methods of production or purification of viral material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29168209P | 2009-12-31 | 2009-12-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2519266T true PT2519266T (pt) | 2017-11-10 |
Family
ID=44227174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT117285403T PT2519266T (pt) | 2009-12-31 | 2011-01-03 | Vacinas de dna infeccioso contra o vírus chikungunya |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9101572B2 (pt) |
| EP (1) | EP2519266B1 (pt) |
| DK (1) | DK2519266T3 (pt) |
| ES (1) | ES2647662T3 (pt) |
| PT (1) | PT2519266T (pt) |
| WO (1) | WO2011082388A2 (pt) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2902787T3 (es) | 2008-07-17 | 2022-03-29 | Medigen Inc | Vacunas de ADNi y procedimientos para utilizar las mismas |
| US9101572B2 (en) * | 2009-12-31 | 2015-08-11 | Medigen, Inc. | Infectious DNA vaccines against chikungunya virus |
| EP2712871A1 (en) | 2012-09-27 | 2014-04-02 | Institut Pasteur | Recombinant Measles virus expressing Chikungunya virus polypeptides and their applications |
| US10538786B2 (en) | 2016-04-13 | 2020-01-21 | Janssen Pharmaceuticals, Inc. | Recombinant arterivirus replicon systems and uses thereof |
| MX2019004499A (es) | 2016-10-17 | 2019-11-18 | Janssen Pharmaceuticals Inc Star | Sistemas de replicón de virus recombinante y usos de estos. |
| AU2017372731B2 (en) * | 2016-12-05 | 2024-05-23 | Janssen Pharmaceuticals, Inc. | Compositions and methods for enhancing gene expression |
| JP2020518648A (ja) | 2017-05-08 | 2020-06-25 | グリットストーン オンコロジー インコーポレイテッド | アルファウイルス新生抗原ベクター |
| US11389531B2 (en) | 2017-12-19 | 2022-07-19 | Janssen Sciences Ireland Unlimited Company | Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines |
| EA202091513A1 (ru) | 2017-12-19 | 2020-09-09 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Вакцины против вируса гепатита b (hbv) и их применение |
| SG11202005792RA (en) * | 2017-12-20 | 2020-07-29 | Vlp Therapeutics Llc | Alphavirus replicon particle |
| BR112020013679A2 (pt) | 2018-01-04 | 2020-12-01 | Iconic Therapeutics, Inc. | anticorpos de fator antitecidual, conjugados anticorpo-fármaco e métodos relacionados |
| CA3089024A1 (en) | 2018-01-19 | 2019-07-25 | Janssen Pharmaceuticals, Inc. | Induce and enhance immune responses using recombinant replicon systems |
| BR112021006614A2 (pt) | 2018-10-08 | 2021-07-20 | Janssen Pharmaceuticals, Inc. | replicons com base em alfavírus para administração de bioterápicos |
| AU2020282369A1 (en) | 2019-05-30 | 2022-01-20 | Seattle Project Corp. | Modified adenoviruses |
| US11759515B2 (en) | 2020-03-09 | 2023-09-19 | Arcturus Therapeutics, Inc. | Compositions and methods for inducing immune responses |
| WO2022032196A2 (en) | 2020-08-06 | 2022-02-10 | Gritstone Bio, Inc. | Multiepitope vaccine cassettes |
| WO2022036170A1 (en) | 2020-08-14 | 2022-02-17 | Arcturus Therapeutics, Inc. | Method of lyophilizing lipid nanoparticles |
| EP4493196A2 (en) * | 2022-03-18 | 2025-01-22 | Medigen, Inc. | Novel rna and dna technology for vaccination against alphaviruses and other emerging and epidemic viruses |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| AU771774B2 (en) * | 1998-12-07 | 2004-04-01 | U.S. Medical Research Institute Of Infectious Diseases | Live attenuated Venezuelan equine encephalitis vaccine |
| US6943015B2 (en) | 2002-12-12 | 2005-09-13 | Ilya Frolov | Large scale production of packaged alphavirus replicons |
| US20060099587A1 (en) * | 2003-06-20 | 2006-05-11 | Johnston Robert E | Alphavirus vectors having attentuated virion structural proteins |
| US7459163B2 (en) | 2004-02-25 | 2008-12-02 | University Of Kansas | Infectious DNA as a vaccine against west nile and other flaviviruses |
| EP1856250B1 (en) | 2005-02-15 | 2013-07-24 | The University of North Carolina At Chapel Hill | New live virus vaccines |
| WO2008030220A2 (en) * | 2005-08-11 | 2008-03-13 | The Board Of Regents Of The University Of Texas System | Chikungunya virus infectious clones and uses thereof |
| KR20080003989A (ko) * | 2006-07-04 | 2008-01-09 | 주식회사 씨젠 | 뎅기 바이러스 핵산 검출용 올리고뉴클레오타이드 |
| WO2008026225A2 (en) * | 2006-09-01 | 2008-03-06 | Bharat Biotech International Limited | A vaccine for chikungunya virus infection |
| WO2009048633A2 (en) * | 2007-10-11 | 2009-04-16 | The Board Of Regents Of The University Of Texas System | Chimeric chikungunya virus and uses thereof |
| US9101572B2 (en) * | 2009-12-31 | 2015-08-11 | Medigen, Inc. | Infectious DNA vaccines against chikungunya virus |
-
2011
- 2011-01-03 US US13/519,948 patent/US9101572B2/en active Active
- 2011-01-03 EP EP11728540.3A patent/EP2519266B1/en active Active
- 2011-01-03 ES ES11728540.3T patent/ES2647662T3/es active Active
- 2011-01-03 DK DK11728540.3T patent/DK2519266T3/da active
- 2011-01-03 PT PT117285403T patent/PT2519266T/pt unknown
- 2011-01-03 WO PCT/US2011/000001 patent/WO2011082388A2/en not_active Ceased
-
2015
- 2015-07-02 US US14/790,960 patent/US9694065B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US9101572B2 (en) | 2015-08-11 |
| ES2647662T3 (es) | 2017-12-26 |
| US20130052225A1 (en) | 2013-02-28 |
| EP2519266A2 (en) | 2012-11-07 |
| DK2519266T3 (da) | 2017-11-06 |
| US20160074500A1 (en) | 2016-03-17 |
| EP2519266A4 (en) | 2013-08-07 |
| WO2011082388A3 (en) | 2011-08-18 |
| WO2011082388A2 (en) | 2011-07-07 |
| US9694065B2 (en) | 2017-07-04 |
| EP2519266B1 (en) | 2017-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2519266T (pt) | Vacinas de dna infeccioso contra o vírus chikungunya | |
| PL2200646T3 (pl) | Szczepionki RNA | |
| EP2552479A4 (en) | INFLUENZA VIRUS VACCINES AND USES THEREOF | |
| EP2403527A4 (en) | LIVELY WEAKED INFLUENZA VIRUS VACCINES WITH MICRORNA REACTION ELEMENTS | |
| HUS1500019I1 (hu) | Hepatitisz C vírus inhibitorok | |
| IL219516A0 (en) | Hepatitis c virus inhibitors | |
| IL219517A0 (en) | Hepatitis c virus inhibitors | |
| ZA201106629B (en) | Hepatitis c virus inhibitors | |
| ZA201105722B (en) | Hepatitis c virus inhibitors | |
| IL215055A0 (en) | Hepatitis c virus inhibitors | |
| EP2475256A4 (en) | HEPATITIS C-VIRUS HEMMER | |
| ZA201107095B (en) | Hepatitis c virus inhibitors | |
| GB0807424D0 (en) | Virus | |
| PL2935313T3 (pl) | Szczepionki przeciwko wirusowi zapalenia wątroby typu b | |
| PL2358386T3 (pl) | Zoptymalizowane szczepionki na grypę | |
| IL222228A0 (en) | Hiv vaccine | |
| ZA201204192B (en) | Herpes simplex virus vaccines | |
| IL212311A0 (en) | Immunoenhancer-linked oligomeric hiv vaccines | |
| PT2331682T (pt) | Vacinas contra a bronquite infecciosa derivadas de estirpes de tipo ib-qx | |
| ZA201008125B (en) | Inactivated live-attenuated bluetongue virus vaccine | |
| GB0912950D0 (en) | Virus | |
| EP2632487A4 (en) | VIRUS VACCINE AND MANUFACTURING METHOD THEREFOR | |
| GB0901056D0 (en) | Virus | |
| GB0823560D0 (en) | Virus | |
| GB0920319D0 (en) | HPV vaccine |